ANL 28.38 Increased By ▲ 0.64 (2.31%)
ASC 16.69 Decreased By ▼ -0.26 (-1.53%)
ASL 23.86 Decreased By ▼ -0.69 (-2.81%)
AVN 94.89 Decreased By ▼ -1.11 (-1.16%)
BOP 9.49 Decreased By ▼ -0.01 (-0.11%)
BYCO 9.62 Decreased By ▼ -0.17 (-1.74%)
DGKC 110.49 Decreased By ▼ -1.46 (-1.3%)
EPCL 47.53 Decreased By ▼ -1.13 (-2.32%)
FCCL 21.30 Decreased By ▼ -0.40 (-1.84%)
FFBL 27.88 Increased By ▲ 0.48 (1.75%)
FFL 19.35 Increased By ▲ 0.23 (1.2%)
HASCOL 14.31 Decreased By ▼ -0.21 (-1.45%)
HUBC 86.14 Decreased By ▼ -0.37 (-0.43%)
HUMNL 7.29 Decreased By ▼ -0.35 (-4.58%)
JSCL 31.60 Decreased By ▼ -0.68 (-2.11%)
KAPCO 40.83 Decreased By ▼ -0.82 (-1.97%)
KEL 4.11 Decreased By ▼ -0.25 (-5.74%)
LOTCHEM 16.16 Decreased By ▼ -0.29 (-1.76%)
MLCF 43.21 Decreased By ▼ -0.47 (-1.08%)
PAEL 39.84 Decreased By ▼ -0.01 (-0.03%)
PIBTL 12.99 Decreased By ▼ -0.06 (-0.46%)
POWER 11.41 Decreased By ▼ -0.27 (-2.31%)
PPL 93.69 Decreased By ▼ -0.81 (-0.86%)
PRL 23.88 Decreased By ▼ -0.37 (-1.53%)
PTC 9.32 Decreased By ▼ -0.08 (-0.85%)
SILK 1.22 Decreased By ▼ -0.05 (-3.94%)
SNGP 44.48 Decreased By ▼ -0.67 (-1.48%)
TRG 109.71 Increased By ▲ 0.73 (0.67%)
UNITY 33.11 Decreased By ▼ -0.99 (-2.9%)
WTL 1.12 Decreased By ▼ -0.02 (-1.75%)
BR100 4,856 Decreased By ▼ -9.94 (-0.2%)
BR30 24,724 Decreased By ▼ -96.85 (-0.39%)
KSE100 45,868 Decreased By ▼ -116.42 (-0.25%)
KSE30 19,061 Decreased By ▼ -87.18 (-0.46%)
World

Plasma from recovered patients shows little benefit in those hospitalized with COVID-19: study

  • The therapy know as convalescent plasma, which delivers antibodies from COVID-19 survivors to infected people, did not significantly improve patients’ health status.
25 Nov 2020

Using blood plasma from COVID-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released on Tuesday from a clinical trial in Argentina.

The therapy know as convalescent plasma, which delivers antibodies from COVID-19 survivors to infected people, did not significantly improve patients’ health status or reduce their risk of dying from the disease any better than a placebo, the study published in The New England Journal of Medicine found.

Despite limited evidence of its efficacy, convalescent plasma, which U.S. President Donald Trump touted in August as a “historic breakthrough,” has been frequently given to patients in the United States.

In October, a small study from India suggested convalescent plasma improved symptoms in COVID-19 patients, such as shortness of breath and fatigue, but did not reduce the risk of death or progression to severe disease after 28 days.

The new Argentine study involved 333 hospitalized patients with severe COVID-19 pneumonia who were randomly assigned to receive convalescent plasma or a placebo.

After 30 days, researchers found no significant differences in patients’ symptoms or health. The mortality rate was nearly the same at 11% in the convalescent plasma group and 11.4% in the placebo group, a difference not deemed statistically significant.

It is still possible that convalescent plasma might help less-sick COVID-19 patients, study leader Dr. Ventura Simonovich of the Hospital Italiano de Buenos Aires said, but more studies would be needed and supplies of the treatment are not scalable.

For patients with severe disease, like the ones in this study, “other therapies based on antibodies could have a role,” he said.